Table 3.

Estimated effectiveness of two doses of BNT162b2 (≥7 days after the second dose) against laboratory-confirmed SARS-CoV-2 outcomes in the oldest age groups (Jan 24 to April 3, 2021)

	Vaccine effectiveness*
	Age ≥65 years	Age ≥75 years	Age ≥85 years
SARS-CoV-2 infection†	94·8% (93·9–95·5)	95·1% (93·9–96·0)	94·1% (91·9–95·7)
Asymptomatic SARS-CoV-2 infection	88·5% (86·4–90·3)	87·5% (84·2–90·1)	83·2% (76·3–88·1)
Symptomatic COVID-19	96·4% (95·9–97·0)	96·7% (95·9–97·4)	96·6% (95·2–97·6)
COVID-19-related hospitalisation	96·8% (96·2–97·3)	97·0% (96·2–97·7)	96·9% (95·5–97·9)
Severe or critical COVID-19-related hospitalisation	97·3% (96·8–97·8)	97·6% (96·8–98·1)	97·4% (95·9–98·3)
COVID-19-related death	96·9% (96·0–97·6)	97·1% (96·0–97·9)	97·0% (94·9–98·3)

Estimates are % (95% CI).

^*Model is adjusted for age group (16–24, 25–34, 35–44, 45–54, 55–64, 65–74, 75–84, and ≥85 years), sex, and calendar week.

^†Includes asymptomatic and symptomatic infections, as well as cases with positive SARS-CoV-2 tests for which the symptom interview portion of the epidemiological investigation was not completed.